Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Visa Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.53 (market cap $29.60B), while Visa Inc trades at $359.53 (market cap $671.74B). The key difference: Visa Inc is far larger — about 22.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Visa Inc pays a 0.74% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | V | |
|---|---|---|
Market Cap | $29.60B | $671.74B |
Sector | Health | Financials |
52-Week High | $491.22 | $370.47 |
52-Week Low | $205.48 | $295.52 |
Enterprise Value | $27.56B | $682.32B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Visa (V) trades at $358.92, down 0.66% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $40B in 2025 to a projected $44.5B in 2026. Analyst consensus is overwhelmingly bullish, with an 85.48% buy rating and a $426.31 price target, suggesting 19% upside. Recent news highlights Visa's AI initiatives, such as Intelligent Commerce Connect, to enhance payment efficiency.
Visa's outlook remains positive due to consistent earnings outperformance, high profit margins, and strategic AI adoption. Risks include rising fintech competition and regulatory pressures. The stock presents a long-term growth opportunity, supported by solid fundamentals and institutional confidence, though investors should monitor competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
